Cell-free DNA in the plasma of patients with systemic sclerosis

Mosca, Marta; Giuliano, Tiziana; Cuomo, Giovanna; Doveri, M.; Tani, Chiara; Curcio, Michele; Abignano, Giuseppina; Feo, Francesca De; Bazzichi, Laura; Rossa, Alessandra Della; Valentini, Gabriele; Bombardieri, Stefano

doi:10.1007/s10067-009-1245-5

Cited by 25 publications

(28 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of rheumatoid arthritis, Leon et al [7] had discovered higher concentrations of free DNA in both plasma and synovial fluid than in healthy subjects while the increasing intensity was correlated with the symptom severity and the level of the tissue damage. Unlike them, Mosca et al [8] did not establish the significant difference in cf-DNA concentration in patients with systemic sclerosis and in healthy subjects, but based on the cf-DNA level they could make a difference between patients with active disease and those with the inactive one.…”

Section: Introductionmentioning

confidence: 95%

“…For many years, free DNA research has been focused on examining the level of free DNA in autoimmune diseases like rheumatoid arthritis [7], systemic sclerosis [8] and primary Sjogren's syndrome [9]. In case of rheumatoid arthritis, Leon et al [7] had discovered higher concentrations of free DNA in both plasma and synovial fluid than in healthy subjects while the increasing intensity was correlated with the symptom severity and the level of the tissue damage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy

Hendy

Motalib

Shafie

et al. 2016

Egyptian Journal of Medical Human Genetics

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is the most heterogeneous chronic autoimmune disease; it is characterized by the presence of auto reactive B and T cells, responsible for the aberrant production of a broad and heterogeneous group of autoantibodies. Recent studies using various detection methods have demonstrated the elevations of circulating DNA in SLE patients.Aim of the study: The current study aimed to measure cell-free DNA (cf-DNA) in SLE patients as a potential tool to predict disease activity and treatment follow up.Subjects and methods: 52 of SLE patients with age ranging from 10 to 48 years were randomly selected and 25 healthy subjects with age and gender matched with the patients were included as a control group. Thorough clinical examination stressing on the central nervous system, vascular, renal, rash, musculoskeletal, mucocutaneous manifestations, and fever was done for patients. The following investigations were done: Complete blood count (CBC), kidney function tests, Creactive protein (CRP), routine autoantibodies for autoimmune diseases, complements (C3 & C4), anti-nucleosome antibodies and cf-DNA by real time PCR (RT-PCR).Results: The levels of anti-double stranded DNA (anti-dsDNA), anti-nucleosome Ab, and cf-DNA were significantly increased in SLE patients compared to controls. The cf-DNA level was correlated to markers of disease severity namely CRP and anti-nucleosome. A significant reduction in levels of cf-DNA, anti-nucleosome Ab and anti-dsDNA was noticed after therapy. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Please cite this article in press as: Hendy OM et al., Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy, Egypt J Med Hum Genet (2015), http://dx. Conclusion:Our findings support that the measurement of cf-DNA appears to be a useful marker in addition to laboratory tests used in SLE diagnosis. High correlation with markers of disease severity suggesting its role in disease pathogenesis and decreasing its level after therapy makes it to be a marker of treatment follow-up.Ó 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

Section: Introductionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy

Hendy

Motalib

Shafie

et al. 2016

Egyptian Journal of Medical Human Genetics

View full text Add to dashboard Cite

show abstract

“…Subsequent research has been mainly focused on the detection and quantification of cfDNA in autoimmune diseases like SLE [7] and rheumatoid arthritis [8]. Elevated levels of cfDNA were also described in other pathological conditions such as cancer [9], sepsis [10], stroke [11] and other autoimmune diseases like systemic sclerosis [12] and primary Sjögreń s syndrome [13]. The origin of cfDNA is not fully understood.…”

Section: Introductionmentioning

confidence: 99%

Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients

Tug

Helmig

Menke

et al. 2014

Cellular Immunology

View full text Add to dashboard Cite

“…More recently, real-time ﬂuorescent quantitative PCR has been developed as the most common method available for quantifying cf-DNA levels [13]. However, since the overall effectiveness of this and other methods is hampered by variation introduced during sample preparation steps, such as DNA extraction and puriﬁcation, the need for novel, accurate detection methods remains.…”

Section: Introductionmentioning

confidence: 99%

Cell-Free Circulating DNA: A New Biomarker for the Acute Coronary Syndrome

Cui¹,

Fan²,

Jing³

et al. 2013

Cardiology

View full text Add to dashboard Cite

Background: In recent studies, concentrations of cell-free circulating DNA (cf-DNA) have been correlated with clinical characteristics and prognosis in several diseases. The relationship between cf-DNA concentrations and the acute coronary syndrome (ACS) remains unknown. Moreover, no data are available for the detection cf-DNA in ACS by a branched DNA (bDNA)-based Alu assay. The aim of the present study was to investigate cf-DNA concentrations in ACS and their relationship with clinical features. Methods: Plasma cf-DNA concentrations of 137 ACS patients at diagnosis, of 60 healthy individuals and of 13 patients with stable angina (SA) were determined using a bDNA-based Alu assay. Results: ACS patients (median 2,285.0, interquartile range 916.4–4,857.3 ng/ml), especially in ST-segment elevation myocardial infarction patients (median 5,745.4, interquartile range 4,013.5–8,643.9 ng/ml), showed a signiﬁcant increase in plasma cf-DNA concentrations compared with controls (healthy controls: median 118.3, interquartile range 81.1–221.1 ng/ml; SA patients: median 202.3, interquartile range 112.7–256.1 ng/ml) using a bDNA-based Alu assay. Moreover, we found positive correlations between cf-DNA and Gensini scoring and GRACE (Global Registry of Acute Coronary Events) scoring in ACS. Conclusion: cf-DNA may be a valuable marker for diagnosing and predicting the severity of coronary artery lesions and risk stratification in ACS.

show abstract

Cell-free DNA in the plasma of patients with systemic sclerosis

Cited by 25 publications

References 23 publications

Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy

Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy

Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients

Cell-Free Circulating DNA: A New Biomarker for the Acute Coronary Syndrome

Contact Info

Product

Resources

About